Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37 episode artwork

EPISODE · Jul 22, 2024 · 39 MIN

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

from Talking Precision Medicine · host Genialis

In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem. Episode 37 links: ⁠⁠⁠⁠TPM E37⁠⁠⁠ for highlights and links from this episode >⁠ ⁠Genialis’ Upcoming Events⁠ ⁠Genialis™ krasID

Episode metadata supplied by the publisher feed · Published Jul 22, 2024

Embed this episode

Ready to play

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

0:00 39:01

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Talking Precision Medicine?

This episode is 39 minutes long.

When was this Talking Precision Medicine episode published?

This episode was published on July 22, 2024.

Can I download this Talking Precision Medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!